Flow Cytometry Panel-Reactive Antibody Screening of Anti-HLA Antibodies in the Waiting List Significantly Reduces the Occurrence of Acute Rejection After Kidney Transplantation

Dedinská, Ivana; Macková, N; Macháleková, Katarína; Miklušica, Juraj; Palkoci, Blažej; Fialová, Jana; Cellar, M; Galajda, Péter; Mokáň, Marián

doi:10.1016/j.transproceed.2017.04.016

Cited by 1 publication

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Depending on the recommendations in individual countries, various methods are used, starting from the biological method PRA-CDC (Panel Reactive Antibodies-Complement Dependent Cytotoxicity) performed in the potential recipient from the moment of entering the transplant waiting list until the procedure is performed, through tests with higher resolution, such as SPA (Solid Phase Assay) using a flow fluorimeter (Luminex), flow cytometer or ELISA technique, allowing to identify the specificity of anti-HLA antibodies and differentiate their classes [2,8,16,17]. These tests should include assessing antibodies in the group of potential recipients and monitoring the humoral response in transplant patients.…”

Section: Discussionmentioning

confidence: 99%

“…These tests should include assessing antibodies in the group of potential recipients and monitoring the humoral response in transplant patients. Determination of anti-HLA specificity before transplantation allows for calculating the virtual PRA, enabling precise donor selection, even for highly immunised recipients [17,18]. In addition, the use of this test after transplantation may facilitate monitoring of the level of alloimmunisation, as well as allowing the detection and assessment of the level of DSA-specific antibodies synthesised de novo in the patient.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, the use of this test after transplantation may facilitate monitoring of the level of alloimmunisation, as well as allowing the detection and assessment of the level of DSA-specific antibodies synthesised de novo in the patient. It appears that monitoring alloantibodies may be an excellent prognostic indicator for graft function, and the titer increase may precede other subclinical symptoms, thus enabling prompt intervention by clinicians [7,9,10,17].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of the level of alloantibodies and selected cytokines in kidney recipients

Wojciechowska‐Koszko¹,

Nowosiad-Magda²,

Krasnodębska-Szponder³

et al. 2022

J Pre Clin Clin Res.

View full text Add to dashboard Cite

Introduction and Objective. Anti-HLA antibodies, especially anti-DSA, are believed to be potentially involved in acute and chronic rejection. New techniques, e.g. flow fluorimetry, can be an excellent supplement to the lymphocytotoxic tests currently used in pre-transplantation practice, and become a tool for monitoring post-transplant immunisation. The aim of the study was to assess the level of cytokines and alloimmunisation in kidney recipients, with the histopathological evaluation of the transplanted kidney biopsy. Materials and method. The study included 62 graft recipients six months after transplant. The level of anti-HLA antibodies was assessed using the x-Map Luminex technique, and the level of cytokines (IFN-γ, IL-4, IL-10, IL-17) was determined using the ELISA test. Results. Histopathological analysis showed that more than 45.2% of patients had changes in the biopsy material. Analysis of the level of alloimmunisation showed that in over 75.8%, the presence was detected of anti-HLA IgM class I antibodies, while anti-HLA IgM class II antibodies were found less often -17.8%. The level of anti-HLA IgG antibodies, depending on the type of the assessed class, respectively, was: class I -43.5% and class II -50%. More than half of the subjects also had anti-MICA antibodies. The level of analysed cytokines was low. Conclusions. The results indicate significant alloimmunisation of kidney recipients, although they do not answer the question whether these are antibodies that appeared de novo after transplantation, and whether anti-DSA antibodies were present among them. For this purpose, the diagnostics should be expanded to include anti-HLA monitoring in the pre-and post-transplant period, using screening tests and tests to identify their specificity. The protocol biopsy and examination of level cytokine can also be a helpful tool in post-transplant diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%